HIT! High Impact Clinical Trials – Why and How

9 Feb 2025 9:45 a.m. 11:15 a.m.
Auditorium Brahmkamal Hall
DavidWheeler Chair University College LondonUnited Kingdom
Time Session
9:45 a.m.
10:03 a.m.
What Have We Learned From CONVINCE?
10:03 a.m.
10:21 a.m.
Design of the ZEUS Trial: Interleukin-6 Inhibition With Ziltivekimab for Cardiovascular Protection in Chronic Kidney Disease
VladoPerkovic Oral Abstract Presenter vlado.perkovic@unsw.edu.auUniversity of New South Wales, Sydney, AustraliaAustralia
10:23 a.m.
10:41 a.m.
A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
JonathanBarratt Oral Abstract Presenter University of Leicester, Leicester, UKUnited Kingdom
10:41 a.m.
10:59 a.m.
Observational Cohort With Embedded Randomized Controlled Trials to Study Pregnancy-Associated Progression of Renal Disease: A Feasibility Study of Dietary Nitrate (Beetroot Juice) to Protect Kidney Function in Pregnant Women With Chronic Kidney Disease
PriscillaSmith Oral Abstract Presenter priscilla.smith@kcl.ac.ukKings College Hospital LondonUnited Kingdom
10:59 a.m.
11:15 a.m.
Design of Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-Proven Primary Glomerular Diseases: Multi-Center, Multi-Arm and Multi-Stage
Selvin Sundar RajMani Oral Abstract Presenter selvinsr@gmail.comIndia
SuceenaAlexander Oral Abstract Presenter Christian Medical College VelloreIndia